Valneva (VALN) Competitors $8.94 -0.24 (-2.61%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. MOR, HCM, BHC, OGN, KNSA, GMTX, CGON, ALVO, CPRX, and TARSShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include MorphoSys (MOR), HUTCHMED (HCM), Bausch Health Cos (BHC), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors MorphoSys HUTCHMED Bausch Health Cos Organon & Co. Kiniksa Pharmaceuticals International Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals MorphoSys (NASDAQ:MOR) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Which has more risk & volatility, MOR or VALN? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Is MOR or VALN more profitable? Valneva has a net margin of -33.87% compared to MorphoSys' net margin of -226.79%. Valneva's return on equity of -34.78% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Valneva -33.87%-34.78%-13.43% Do institutionals & insiders hold more shares of MOR or VALN? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor MOR or VALN? In the previous week, Valneva had 17 more articles in the media than MorphoSys. MarketBeat recorded 17 mentions for Valneva and 0 mentions for MorphoSys. Valneva's average media sentiment score of 0.28 beat MorphoSys' score of 0.00 indicating that Valneva is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Valneva Neutral Which has better valuation and earnings, MOR or VALN? Valneva has lower revenue, but higher earnings than MorphoSys. Valneva is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Valneva$183.52M4.19-$13.25M-$0.98-9.12 Do analysts rate MOR or VALN? Valneva has a consensus target price of $15.00, suggesting a potential upside of 67.79%. Given Valneva's stronger consensus rating and higher possible upside, analysts clearly believe Valneva is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Valneva 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryValneva beats MorphoSys on 12 of the 16 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$788.81M$10.93B$5.86B$10.15BDividend YieldN/A1.84%5.68%4.59%P/E Ratio-9.1221.1374.5225.93Price / Sales4.1931.03536.78122.58Price / Cash93.9524.8137.5660.44Price / Book3.713.5212.166.29Net Income-$13.25M$210.50M$3.28B$270.77M7 Day Performance3.35%-0.18%0.98%3.36%1 Month Performance-4.89%3.91%7.20%6.41%1 Year Performance28.08%-10.02%63.06%28.26% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.783 of 5 stars$8.94-2.6%$15.00+67.8%+31.1%$788.81M$183.52M-9.12700Short Interest ↓MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED2.6066 of 5 stars$16.11+0.9%$28.00+73.8%-2.6%$2.79B$630.20M0.001,811News CoverageAnalyst DowngradeGap UpBHCBausch Health Cos4.6295 of 5 stars$7.33-0.3%$9.00+22.9%+13.7%$2.72B$9.63B28.1720,700Positive NewsOGNOrganon & Co.4.5156 of 5 stars$10.48+0.9%$17.33+65.5%-47.1%$2.70B$6.40B3.894,000Positive NewsKNSAKiniksa Pharmaceuticals International2.1473 of 5 stars$36.57+2.4%$41.17+12.6%+52.1%$2.65B$423.24M914.48220Short Interest ↑GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+21.0%$2.63BN/A-60.7630CGONCG Oncology2.185 of 5 stars$33.69+1.9%$53.91+60.0%-9.2%$2.52B$1.14M-19.0361Gap UpHigh Trading VolumeALVOAlvotech3.2488 of 5 stars$8.16-2.0%$14.00+71.6%-25.2%$2.51B$491.98M35.481,032Short Interest ↓CPRXCatalyst Pharmaceuticals4.9144 of 5 stars$20.08-1.0%$33.20+65.3%+4.1%$2.48B$491.73M12.1780Positive NewsInsider TradeTARSTarsus Pharmaceuticals2.7356 of 5 stars$56.89-1.3%$66.67+17.2%+63.1%$2.43B$182.95M-24.4250Positive NewsInsider Trade Related Companies and Tools Related Companies MOR Alternatives HCM Alternatives BHC Alternatives OGN Alternatives KNSA Alternatives GMTX Alternatives CGON Alternatives ALVO Alternatives CPRX Alternatives TARS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
